Amgen (NASDAQ:AMGN) Releases FY 2025 Earnings Guidance

Amgen (NASDAQ:AMGN) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 20.000-21.200 for the period, compared to the consensus earnings per share estimate of 20.820. The company issued revenue guidance of $34.3 billion-$35.7 billion, compared to the consensus revenue estimate of $34.5 billion.

Amgen Trading Up 0.1 %

AMGN stock traded up $0.15 during trading on Tuesday, hitting $289.02. The company had a trading volume of 3,256,680 shares, compared to its average volume of 3,136,982. The stock has a market cap of $155.36 billion, a price-to-earnings ratio of 37.01, a PEG ratio of 2.87 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a 50-day moving average price of $270.95 and a 200-day moving average price of $303.82. Amgen has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. As a group, analysts predict that Amgen will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.29%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is 115.24%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Sanford C. Bernstein began coverage on Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. Piper Sandler lowered their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. TD Cowen lifted their price target on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Leerink Partners reduced their price target on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $314.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.